Key result
SCN5A non-missense and transmembrane/pore missense mutations were associated with a higher risk of ajmaline-induced PVCs compared to no mutation (29% and 24% vs 3%; P<0.001).
Why the study?
Does the presence, type, and topology of SCN5A mutation predict PVC occurrence during ajmaline infusion in patients without baseline type-1 ECG?
Observational (n=416)
Does the presence, type, and topology of SCN5A mutation predict PVC occurrence during ajmaline infusion in patients without baseline type-1 ECG?
Absolute Event Rate: 29% vs 3%
p-value: p=<0.001
In patients without baseline type-1 ECG, specific SCN5A mutations (non-missense and transmembrane/pore missense) strongly predict the risk of ventricular arrhythmias during sodium channel blocker provocation.
No takes yet. Share an insight, caveat, or question.
SCN5A carriers may warrant closer monitoring during ajmaline challenge; hypothesis-generating for genotype-stratified protocols.
Amin et al. (2018) conducted an observational in Suspected Brugada syndrome without baseline type-1 ECG (n=416). SCN5A mutation (non-missense or missense-TP) vs. No SCN5A mutation was evaluated on Ajmaline-induced premature ventricular contractions (PVCs) (p=<0.001). SCN5A non-missense and transmembrane/pore missense mutations were associated with a higher risk of ajmaline-induced PVCs compared to no mutation (29% and 24% vs 3%; P<0.001).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: